Fig 1.
CYP4B1 mRNA expression profiles in patients with LUAD from TCGA and GEO dataset cohorts.
(A–D) CYP4B1 mRNA expression in LUAD tissues and normal controls from a TCGA cohort (A), GSE30219 cohort (B), GSE31210 cohort (C) and GSE32863 cohort (D). (E) ROC curves showing the diagnostic value of CYP4B1 in LUAD (red curve, data from TCGA cohort; purple curve, data from GSE30219 cohort; blue curve, data from GSE32863 cohort; green curve, data from GSE31210 cohort). ****p<0.0001. LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; ROC, receiver operating characteristic.
Table 1.
Correlation between the clinicopathological parameters and CYP4B1 expression in LUAD.
Fig 2.
Low CYP4B1 expression was associated with unfavorable survival in patients with LUAD.
(A–C) Kaplan-Meier curves of OS in patients with LUAD from a TCGA cohort (A), GSE30219 cohort (B) and GSE31210 cohort (C). (D-F) Kaplan-Meier curves of RFS in patients with LUAD from a TCGA cohort (D), GSE30219 cohort (E) and GSE31210 cohort (F). LUAD, lung adenocarcinoma; OS, overall survival; TCGA, The Cancer Genome Atlas; RFS, recurrence-free survival.
Fig 3.
Forest plots of Cox regression analysis.
(A) Forest plots showing univariate and multivariate analysis of OS in patients with LUAD. (B) Forest plots showing univariate and multivariate analysis of RFS in patients with LUAD. *p<0.05. OS, overall survival; LUAD, lung adenocarcinoma; RFS, recurrence-free survival.
Fig 4.
CYP4B1 expression was modulated by its gene alterations and DNA methylation in LUAD.
(A) Genetic alterations of CYP4B1 in LUAD. (B) Heatmap of CYP4B1 expression, DNA copy number alterations (gistic2 linear and gistic2 thresholded), and DNA methylation (Methylation 450k). (C) CYP4B1 expression correlates with its linear copy number values by linear regression analysis. (D) DNA methylation level of cg23440155 and cg23414387 sites is significantly upregulated in LUAD tissues when compared with adjacent normal tissues. (E) CYP4B1 expression correlates with cg23440155 and cg23414387 methylation levels by a linear regression analysis. LUAD, lung adenocarcinoma.
Fig 5.
Differentially expressed genes correlated with CYP4B1 in LUAD.
(A) Volcano plot showing differentially expressed genes significantly associated with CYP4B1 (FDR<0.05; |Pearson’s r|>0.2). (B, C) Heatmaps showing the top 50 significant genes positively and negatively correlated with CYP4B1 in LUAD. (D-F) The top three significant genes demonstrating positive co-expression with CYP4B1 in LUAD. (D) Pearson correlation of CYP4B1 expression with PEBP4, C16orf89, and SFTPD. (E) The mRNA expression profiles of PEBP4, C16orf89, and SFTPD in LUAD tissues when compared with normal lung tissues. (F) Survival analysis of PEBP4, C16orf89, and SFTPD in LUAD. FDR, false discovery rate; LUAD, lung adenocarcinoma.
Fig 6.
Gene ontology and GSEA analysis categorized by the KEGG pathway of the genes co-expressed with CYP4B1 in TCGA-LUAD.
GSEA, Gene set enrichment analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; TCGA, The Cancer Genome Atlas; LUAD, lung adenocarcinoma.